{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:08:35Z","timestamp":1793984915522,"version":"4.8.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2021QH205"],"award-info":[{"award-number":["ZR2021QH205"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2019PF017"],"award-info":[{"award-number":["ZR2019PF017"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.heliyon.2024.e27832","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T23:30:36Z","timestamp":1710286236000},"page":"e27832","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Knowledge domains and emerging trends in immune-related adverse events from immune checkpoint inhibitors: A bibliometrics and visualized analysis"],"prefix":"10.1016","volume":"10","author":[{"given":"Jun","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.heliyon.2024.e27832_bib1","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.3390\/cancers14061404","article-title":"Impact of proton pump inhibitors and histamine-2-receptor antagonists on non-small cell lung cancer immunotherapy: a systematic review and meta-analysis","volume":"14","author":"Rizzo","year":"2022","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e27832_bib2","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1080\/13543784.2022.2009456","article-title":"Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects","volume":"31","author":"Rizzo","year":"2022","journal-title":"Expet Opin. Invest. Drugs"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e27832_bib3","article-title":"Toxicities of immune checkpoint inhibitors: itis-ending adverse reactions and more","volume":"12","author":"Ellithi","year":"2020","journal-title":"Cureus"},{"issue":"13","key":"10.1016\/j.heliyon.2024.e27832_bib4","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMc1509660","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Valsecchi","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e27832_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103596","article-title":"The impact of gender on the efficacy of immune checkpoint inhibitors in cancer patients: the MOUSEION-01 study","volume":"170","author":"Santoni","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e27832_bib6","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1245\/s10434-008-0104-y","article-title":"CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues","volume":"15","author":"Phan","year":"2008","journal-title":"Ann. Surg Oncol."},{"key":"10.1016\/j.heliyon.2024.e27832_bib7","article-title":"Etal. Knowledge mapping of immunotherapy for hepatocellular carcinoma: a bibliometric study","volume":"13","author":"Shen","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e27832_bib8","doi-asserted-by":"crossref","first-page":"R207","DOI":"10.1530\/EC-20-0342","article-title":"Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review","volume":"9","author":"Stelmachowska-Bana\u015b","year":"2020","journal-title":"Endoc Connect"},{"issue":"17","key":"10.1016\/j.heliyon.2024.e27832_bib9","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-09-1024","article-title":"A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma","volume":"15","author":"Weber","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27832_bib10","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e27832_bib11","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(18)30144-X","article-title":"Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study","volume":"19","author":"Garassino","year":"2018","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e27832_bib12","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e27832_bib13","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.jtho.2017.08.022","article-title":"Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with nivolumab: a prospective cohort study","volume":"12","author":"Teraoka","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e27832_bib14","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jamaoncol.2018.6258","article-title":"Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial","volume":"5","author":"Disis","year":"2019","journal-title":"JAMA Oncol."},{"issue":"19","key":"10.1016\/j.heliyon.2024.e27832_bib15","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","article-title":"Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders","volume":"36","author":"Leonardi","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e27832_bib16","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1158\/2326-6066.CIR-17-0755","article-title":"Safety and efficacy of Re-treating with immunotherapy after immune-related adverse events in patients with NSCLC","volume":"6","author":"Santini","year":"2018","journal-title":"Cancer Immunol. Res."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e27832_bib17","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e27832_bib18","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jamaoncol.2019.1022","article-title":"Etal. Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer","volume":"5","author":"Simonaggio","year":"2019","journal-title":"JAMA Oncol."},{"issue":"17","key":"10.1016\/j.heliyon.2024.e27832_bib19","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e27832_bib20","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.heliyon.2024.e27832_bib21","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Etal. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"suppl_4","key":"10.1016\/j.heliyon.2024.e27832_bib22","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e27832_bib23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.heliyon.2024.e27832_bib24","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Etal. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e27832_bib25","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27832_bib26","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.heliyon.2024.e27832_bib27","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.heliyon.2024.e27832_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.925924","article-title":"Visualizing knowledge evolution trends and research hotspots of artificial intelligence in colorectal cancer: a bibliometric analysis","volume":"12","author":"Liu","year":"2022","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e27832_bib29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11912-020-0897-9","article-title":"Immune-related adverse events (irAEs): diagnosis, management, and clinical pearls","volume":"22","author":"Darnell","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.heliyon.2024.e27832_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.730320","article-title":"Safety and efficacy of the rechallenge of immune checkpoint inhibitors after immune-related adverse events in patients with cancer: a systemic review and meta-analysis","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e27832_bib31","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e27832_bib32","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/14740338.2021.1915279","article-title":"Vitiligo induced by immune checkpoint inhibitors in melanoma patients: an expert opinion","volume":"20","author":"Lommerts","year":"2021","journal-title":"Expet Opin. Drug Saf."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e27832_bib33","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1089\/thy.2018.0116","article-title":"Immune-related thyroiditis with immune checkpoint inhibitors","volume":"28","author":"Iyer","year":"2018","journal-title":"Thyroid"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e27832_bib34","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1089\/thy.2019.0726","article-title":"Overt thyroid dysfunction and anti-thyroid antibodies predict response to anti-PD-1 immunotherapy in cancer patients","volume":"30","author":"Basak","year":"2020","journal-title":"Thyroid"},{"key":"10.1016\/j.heliyon.2024.e27832_bib35","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.3390\/cancers14112687","article-title":"Clinical presentation of immune-related endocrine adverse events during immune checkpoint inhibitor treatment","volume":"14","author":"Chieng","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.heliyon.2024.e27832_bib36","article-title":"Pancreatic injury following immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"24","key":"10.1016\/j.heliyon.2024.e27832_bib37","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.2169\/internalmedicine.7366-21","article-title":"Fatal immune checkpoint inhibitor-related pancreatitis","volume":"60","author":"Ueno","year":"2021","journal-title":"Intern. Med. (Tokyo)"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27832_bib38","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1136\/gutjnl-2012-302779","article-title":"Classification of acute pancreatitis\u20142012: revision of the Atlanta classification and definitions by international consensus","volume":"62","author":"Banks","year":"2013","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e27832_bib39","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1080\/1744666X.2020.1804362","article-title":"etal. Immune checkpoint inhibitor-induced inflammatory arthritis: identification and management","volume":"16","author":"Williams","year":"2020","journal-title":"Expet Rev. Clin. Immunol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27832_bib40","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/imr.12832","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis as a model of autoimmune arthritis","volume":"294","author":"Cappelli","year":"2020","journal-title":"Immunol. Rev."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27832_bib41","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41467-022-29539-3","article-title":"Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy","volume":"13","author":"Kim","year":"2022","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e27832_bib42","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/s41581-022-00630-8","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury","volume":"18","author":"Sprangers","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e27832_bib43","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000520798","article-title":"Acute kidney injury induced by immune checkpoint inhibitors","volume":"8","author":"Tian","year":"2022","journal-title":"Kidney Dis."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e27832_bib44","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41585-022-00676-0","article-title":"Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma","volume":"20","author":"Rosellini","year":"2023","journal-title":"Nat. Rev. Urol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e27832_bib45","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.3390\/cancers15051629","article-title":"Predictive biomarkers for checkpoint inhibitor immune-related adverse events","volume":"15","author":"Les","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.heliyon.2024.e27832_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.779691","article-title":"Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors","volume":"13","author":"Chennamadhavuni","year":"2022","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e27832_bib47","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1007\/s00262-021-02855-1","article-title":"Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors","volume":"70","author":"Tyan","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e27832_bib48","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.it.2021.02.006","article-title":"Predicting and preventing immune checkpoint inhibitor toxicity: targeting cytokines","volume":"42","author":"Kang","year":"2021","journal-title":"Trends Immunol."},{"key":"10.1016\/j.heliyon.2024.e27832_bib49","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41571-021-00597-8","article-title":"Harnessing big data to characterize immune-related adverse events","volume":"19","author":"Jing","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e27832_bib50","article-title":"Elucidation of the application of blood test biomarkers to predict immune-related adverse events in atezolizumab-treated NSCLC patients using machine learning methods","volume":"13","author":"Zhou","year":"2022","journal-title":"Front. Immunol."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024038635?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024038635?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T20:35:11Z","timestamp":1782246911000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024038635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2405844024038635"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27832","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Knowledge domains and emerging trends in immune-related adverse events from immune checkpoint inhibitors: A bibliometrics and visualized analysis","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27832","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e27832"}}